Eliminating the HIV reservoir

Current HIV/AIDS Reports

Volumn 9, Issue 2, 2012, Pages 121-131

  Lafeuillade, Alain ^a  

^a GENERAL HOSPITAL   (France)

Author keywords

Histone deacetylase inhibitors; HIV curative strategies; HIV cure; HIV functional cure; HIV gene therapy; HIV persistence; HIV Reservoirs; HIV sanctuaries; HIV sterilizing cure; HIVeradication; HIVremission; Towards HIV cure; Zinc finger nucleases

Indexed keywords

ATAZANAVIR; AURANOFIN; BRYOSTATIN; DISULFIRAM; EFAVIRENZ; EMTRICITABINE; HISTONE DEACETYLASE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 32; INTERLEUKIN 7; MINOCYCLINE; RALTEGRAVIR; TENOFOVIR; VIRUS ANTIGEN; VIRUS DNA; VORINOSTAT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; DENDRITIC CELL; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG TISSUE LEVEL; DRUG TREATMENT FAILURE; GOLD STANDARD; HALF LIFE TIME; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; IMMUNOREGULATION; INTESTINE LYMPHATIC TISSUE; INTRACELLULAR SPACE; LYMPH NODE; LYMPHOID TISSUE; MACROPHAGE; MEMORY T LYMPHOCYTE; MULTIPOTENT STEM CELL; NONHUMAN; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TH17 CELL; VIREMIA; VIRUS CARRIER; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION; DISEASE CARRIER; GENE THERAPY; IMMUNOLOGY; REVIEW; T LYMPHOCYTE; VIROLOGY; VIRUS LATENCY;

ANTI-HIV AGENTS; DISEASE RESERVOIRS; GENE THERAPY; HIV INFECTIONS; HUMANS; T-LYMPHOCYTES; VIRUS LATENCY;

EID: 84864014553     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-012-0115-y     Document Type: Article

References (98)

1. Dieffenbach CW, Fauci AS. Thirty years of HIV and AIDS: future challenges and opportunities. Annals Intern Med. 2011;154:766-71.
2. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science. 2009;323:1304-7.
3. Trono D, Van Lint C, Rouzioux C, et al. HIV persistence and the prospect of long-term drug-free remission for HIV-infected individuals. Science. 2010;329:174-80.
4. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nature Med. 2009;15:893-901.
5. Redel L, Le Douce V, Cherrier T, et al. HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes. J Leukoc Biol. 2010;87:575-88.
6. Cobos-Jiménez V, Booiman T, Hamann J, Kootstra NA. Macrophages and HIV-1. Curr Opin HIVAIDS. 2011;6:385-90.
7. Marsden MD, Avancena P, Kitchen CM, Hubbard T, Zack JA. Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages. Antimicrob Agents Chemother. 2011;55:3696-702.
8. Carter CC, Onafuwa-Nuga A, McNamara LA, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nature Med. 2010;16:446-51.
9. Carter CC, McNamara LA, Onafuwa-Nuga A, et al. HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe. 2011;9:223-34.
10. Trono D, Marzetta F. Profaning the ultimate sanctuary: HIV latency in hematopoietic stem cells. Cell Host Microbe. 2011;9:170-2.
11. Palmer S. Characterizing latent HIV reservoirs. Paper presented at the 5th International Workshop on HIV Persistence, Reservoirs and Eradication Strategies. St Maarten, West Indies: December 6-9, 2011. Global Antiviral Journal 2011;7(suppl 2):11-12. Available at http://www.ihlpress.com/gaj-issues- new.html.
12. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antire-troviral therapy. JAMA. 1999;282:1627-32. (Pubitemid 29513968)
13. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003;41:4531-6. (Pubitemid 37259753)
14. Brennan TP, Woods JO, Sedaghat AR, et al. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol. 2009;83:8470-81.
15. + T cells. J Virol. 2011;85:5220-3.
16. Lerner P, Guadalupe M, Donovan R, et al. The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy. J Virol. 2011;85:4772-82.
17. Sharkey M, Babic DZ, Greenough T, et al. Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog. 2011;7:e1001303.
18. Josefsson L, Dahl V, Palmer S. Can HIV infection be eradicated through use of potent antiviral agents? Curr Opin Infect Dis. 2010;23:628-32.
19. Maldarelli F. Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication. Curr Opin HIV AIDS. 2010;6:49-56.
20. McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010;50:912-9.
21. + T cell response. J Infect Dis. 2011;203:960-8.
22. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification on HAART-suppressed subjects. Nature Med. 2010;16:460-5.
23. Kovacs C, Brunetta J, Chun TW, et al. Effect of intensification of long-term highly active antiretroviral therapy (HAART) with raltegravir on proviral HIV-1 DNA in gut associated lymphoid tissue (GALT): a randomized, placebo controlled trial [abstract MOAA0103]. Paper presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy: July 17-20, 2011.
24. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010;24:2451-60.
25. Yukl SA, Gianella S, Sinclair E, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis. 2010;202:1553-61.
26. Smurzynski M, Wu K, Letendre S, et al. Effect of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS. 2011;25:357-65.
27. Shen L, Peterson S, Sedaghat AR, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med. 2008;14:762-6. (Pubitemid 351951518)
28. Shen L, Siliciano RF. Achieving a quantitative understanding of antiretroviral drug efficacy. Clin Infect Dis. 2010;51:1105-6.
29. Sigal A, Kim JT, Balazs AB, et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature. 2011;477:95-8.
30. Schacker T, Stevenson M, Fletcher C. Anatomic HIV reservoirs. Paper presented at the 5th International Workshop on HIV Persistence, Reservoirs and Eradication Strategies. St Maarten, West Indies: December 6-9, 2011. Global Antiviral Journal 2011;7(suppl 2):28-29. Available at http://www.ihlpress.com/ gaj-issues-new.html.
31. Cohen J. Tissue says blood is misleading, confusing HIV cure efforts. Science. 2011;334:1614.
32. Rong L, Perelson AS. Asymetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. Math Biosci. 2009;217:77-87.
33. Chomont N, DaFonseca S, Vandergeeten C, Ancuta P, Sekaly RP. Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV. Curr Opin HIVAIDS. 2011;6:30-6.
34. Vandergeeten C, Da Fonseca S, Sereti I, et al. Differential impact of IL-7 and IL-15 on HIV reservoir persistence [abstract MOAA0101]. Paper presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy: July 17-20, 2011.
35. Lewis MG, DaFonseca S, Chomont N, et al. Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS. 2011;25:1347-56.
36. Szeto GL, Brice AK, Yang HC, et al. Minocyclin Attenuated HIV Infection and Reactivation by Suppressing Cellular Activation in Human CD4+ T Cells. J Infect Dis. 2010;201:1132-40.
37. DaFonseca S, Chomont N, El Far M, et al. Purging the HIV-1 reservoir through the disruption of the PD-1 pathway persistence [abstract 268]. Paper presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA: Feb 27-Mar 2, 2011.
38. Porichis F, Kwon DS, Zupkosky J, et al. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood. 2011;118:965-74.
39. Chomont N. New concept in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference [abstract WESY0101]. Paper presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy: July 17-20, 2011.
40. Lewin S. Contribution of the immune system to HIV persistence. [abstract WEWS0303]. Paper presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy: July 17-20, 2011.
41. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med. 2009;60:471-84.
42. Chege D, Sheth PM, Kain T, et al. Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS. 2011;25:741-9.
43. Boasso A. Wounding the immune system with its own blade: HIV-induced tryptophan catabolism and pathogenesis. Curr Med Chem. 2011;18:2247-56.
44. Favre D, Mold J, Hunt PW, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of Th17 to regulatory T cells in HIV disease. Sci Transl Med. 2010;2:32ra36.
45. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J infect Dis. 2008;197:126-33. (Pubitemid 351263476)
46. Autran B, Descours B, Avettand-Fenoel V, Rouzioux C. Elite controllers as a model of functional cure. Curr Opin HIV AIDS. 2011;6:181-7.
47. Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV infection. AIDS. 2010;24:1598-15601.
48. Lewin SR, Rouzioux C. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS. 2011;25:885-97.
49. Lafeuillade A. Potential strategies for an HIV infection cure. HIV Clin Trials. 2011;12:121-30.
50. Pandrea I, Gaufin T, Gautam R, et al. Functional Cure of SIVagm Infection in Rhesus Macaques Results in Complete Recovery of CD4+ T cells and Is Reverted by CD8+ Cell Depletion. PLoS Pathog. 2011;7:e1002170.
51. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360:692-8.
52. Allers K, Hütter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5 A32/A32 stem cell transplantation. Blood. 2011;117:2791-9.
53. Hütter G, Thiel E. Allogenic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no.2. AIDS. 2011;25:273-4.
54. Quan Y, Liang C, Brenner BG, Wainberg MA. Multidrug-Resistant Variants of HIV Type 1 (HIV-1) Can Exist in cells as Defective Quasispecies and Be rescued by superinfection with Other Defective HIV-1 Variants. J Infect Dis. 2009;200:1479-83.
55. Liszewski MK, Yu JJ, O'Doherty U. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods. 2009;47:254-60.
56. Graf EH, Mexas AM, Yu JJ, et al. Elite suppressors harbour low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+patients on and off ART. PLoS Pathog. 2011;7:e1001300.
57. Agosto LM, Liszewski MK, Mexas A, et al. Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs. Virology. 2011;409:46-53.
58. Schacker T. New tools to track HIV. Nat Med. 2010;16:373-4.
59. Richman DD. Challenges to finding a cure for HIV infection. Curr Opin HIVAIDS. 2011;6:1-3.
60. Chun TW, Justement JS, Murray D, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implication for eradication. AIDS. 2010;24:2803-8.
61. Iglesias-Ussel MD, Romerio F. HIV reservoirs: the new frontier. AIDS Rev. 2011;13:13-29.
62. Avettand-Fenoel V, Prazuck T, Hocqueloux L, et al. HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors. AIDS. 2008;22:1880-2.
63. Li Q, Skinner PJ, Duan L, Haase AT. A technique to simultaneously visualize virus-specific CD8+ T cells and virus-infected cells in situ. J Vis Exp. 2009;30. pii:1561.
64. Haase AT, Henry K, Zupancic M, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science. 1996;274:985-9. (Pubitemid 26398421)
65. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol. 2010;1:11-23.
66. Engel ME, Hiebert SW. The enemy within: dormant retroviruses awaken. Nat Med. 2010;16:517-8.
67. Schleifman EB, Bindra R, Leif J, et al. Targeted Disruption of the CCR5 Gene in Human Hematopoietic Stem Cells Stimulated by Peptide Nucleic Acids. Chem Biol. 2011;18:1189-98.
68. Nath A, Clements JE. Eradication of HIV from the brain: reasons for pause. AIDS. 2011;25:577-80.
69. Ananworanich J, Schetz A, Sereti A, et al. Mega-HAART suppresses HIV viremia, reduces viral reservoir, and restores immunity in peripheral blood and sigmoid colon of acute HIV-infected subjects [abstract 516]. Paper presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA: Feb 27-Mar 2, 2011.
70. Markowitz M, Evering T, Caskey M, et al. A randomized open-label trial of 5-drug vs 3-drug standard PI-based cART initiated during acute and early HIV-1 infection: 48-weeks results [abstract 148LB]. Paper presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA: Feb 27-Mar 2, 2011.
71. Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology. 2009;6: III.
72. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbial. 2009;7:798-812.
73. Keedy KS, Kashuba AD, Margolis DM. Therapy for persistent HIV. Trends Pharmacol Sci. 2010;31:206-11.
74. Bowman MC, Archin NM, Margolis DM. Pharmaceutical approaches to eradication of persistent HIV infection. Expert Rev Mol Med. 2009;11:e6.
75. Choudhary SK, Margolis DM. Curing HIV: pharmacologic approaches to target HIV-1 latency. Ann Rev Pharmacol Toxicol. 2011;51:397-418.
76. Margolis DM. Mechanisms of HIV latency: an emerging picture of complexity. Curr HIV/AIDS Rep. 2010;7:37-43.
77. Margolis DM. Eradication therapies for HIV infection: time to begin again. AIDS Res Hum Retroviruses. 2011;4:347-53.
78. Margolis DM. Histone deacetylase inhibitors and HIV latency. Curr Opin HIVAIDS. 2011;6:25-9.
79. Matalon S, Rasmussen TA, Dinarello CA. Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med. 2011;17:466-72.
80. Choi BS, Lee HS, Oh YT, et al. Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1. AIDS. 2010;24:609-11.
81. Cohen J. The emerging race to cure HIV infections. Science. 2011;332:787-9.
82. Perez M, de Vinuesa AG, Sanchez-Duffhues G, et al. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res. 2010;8:418-29.
83. Kovochich M, Marsden MD, Zack JA. Activation of latent HIV using drug-loaded nanoparticles. PLoS ONE. 2011;6:e18270.
84. Burnett JC, Lim KI, Calafi A, Rossi JJ, Schaffer DV, Arkin AP Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol. 2010;84:5958-74.
85. Wang FX, Xu Y, Sullivan J, Souder E, et al. IL-7 is a potent and proviral-strain specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART J Clin Invest. 2005;115:128-37. (Pubitemid 40385513)
86. Bosque A, Famiglietti M, Weyrich AS, Goulston C, Planelles V Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog. 2011;7: e1002288.
87. Imamichi H, DeGray G, Asmuth DM, et al. HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS. 2011;25:159-64.
88. Xing S, Bullen CK, Shroff NS, et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol. 2011;85:6060-4.
89. Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nature Biotechnol. 2010;28:839-47.
90. Deeks SG, McCune JM. Can HIV be cured with stem cell therapy? Nature Biotechnol. 2010;28:807-10.
91. Lalezari J, Mitsuyasu R, Deeks S, et al. Successful and persistent engraftment of ZFN-M-R5-D autologous CD4 T Cells (SB-728-T) in aviremic HIV-infected subjects on HAART [abstract 46]. Paper presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA: Feb 27-Mar 2, 2011.
92. Tebas P, Levine B, Binder G, et al. Disruption of CCR5 in zinc finger nuclease treated CD4 T cells: phase I trials [abstract 165]. Paper presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA: Feb 27-Mar 2, 2011.
93. Ando D, Tang WW, Stein D, June C, et al. HAART Treatment Interruption following Adoptive Transfer of Zinc Finger Nuclease (ZFN) Modified Autologous CD4 T-cells (SB-728-T) to HIV-infected Subjects Demonstrates Durable Engraftment and Suppression of Viral Load [abstract H2-794a]. Paper presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL: 17-20 September, 2011.
94. McNeer NA, Chin JY, Schleifman EB, et al. Nanoparticles deliver triplex-forming PNAs for site-specific genomic recombination in CD34+ human hematopoietic progenitors. Mol Ther. 2011;1:172-80.
95. DiGiusto DL, Krishnan A, Li L, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34+ cells in patients undergoing transplantation for AIDS-related lymphoma. Sci transl Med. 2010;2:36ra43.
96. Lunzen J, Fehse B, Hauber J. Gene therapy strategies: can we eradicate HIV? Curr HIV/AIDS Rep. 2011;8:78-84.
97. Levin A, Hayouka Z, Friedler A, Loyter A. Specific eradication of HIV-1 from infected cultured cells. AIDS Res Ther. 2010;7:31.
98. Berger EA, Pastan I. Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog. 2010;6:e1000803.